|
|
|
A new report details the economic impact of America’s industrial bioeconomy, while a few recent studies define and quantify the impacts of long COVID. We have details, plus more on reducing the industry’s emissions from BIO 2024. (707 words, 3 minutes, 32 seconds) |
|
|
|
|
|
|
U.S. ‘industrial bioeconomy’ adds $210.4B and 643,992 jobs, says report |
|
|
The U.S. “industrial bioeconomy” contributed $210.4 billion to the GDP and added 643,992 domestic jobs in 2023, a report released Tuesday showed.
A key finding: In 2023, the 53,302 direct industrial bioeconomy jobs each supported 11.08 additional U.S. jobs, the report said. Industrial bioeconomy workers averaged $133,600 annually and the subsector drove $49.4 billion in direct and indirect wages.
“A significant jobs multiplier”: “Relative to other industrial sectors, the extended domestic supply chain of the U.S. industrial bioeconomy generates outsized secondary economic benefits,” the report said.
The top 10 states for direct industrial bioeconomy employment: California (6,204), Illinois (6,102), Iowa (5,771), Nebraska (3,114), Georgia (3,004), Minnesota (2,006), Texas (1,916), Massachusetts (1,740), North Carolina (1,707), Ohio (1,673).
This is an American industry that… - relies almost exclusively on local suppliers;
- depends on labor, biomass and other materials, goods, and services that cannot be economically sourced overseas;
- is a natural outgrowth of U.S. leadership in the sciences;
- has remained a consistent source of domestic jobs and manufacturing strength.
What they’re saying: “Our abundant natural resources, unparalleled agricultural sector, and strong leadership in the sciences have combined to establish America’s industrial bioeconomy as a powerful engine for U.S. growth,” said Curt Blades, SVP of the Association of Equipment Manufacturers (AEM), a report co-sponsor.
The report focused on the bioeconomy subsector producing industrial bioproducts and outputs, including biofuels. It did not include biopharma or firms directly producing food or beverages. Authored by TEConomy Partners, the report was commissioned by a group of innovators, manufacturers, and trade associations.
|
|
|
BIO 2024: How can we build a more sustainable biopharma ecosystem? |
|
|
|
Healthcare is responsible for about 4-5% of greenhouse gas emissions worldwide—but we can make an impact by addressing the emissions in the biopharma supply chain, said panelists at the 2024 BIO International Convention.
The challenge: “Trying to create life-saving drugs does use a lot of materials and a lot of resources—and a lot of those resources can’t be reused at the moment,” said Rachel Kaufman, Head of Global Sustainability at Avantor, in an interview with Good Day BIO Live.
“A challenge leads to innovations,” she said. We see “collaboration from the customer side to the suppliers to the raw materials manufacturers to come together” and develop innovative solutions, especially around recycling plastics.
Advancing biotech innovation is key: “We talk about a healthy planet being good for healthy people. Healthy people also create a healthy planet,” she said—she explains why. |
|
|
Catch up on BIO 2024 with Good Day BIO Live |
|
|
- Keep an eye on Bio.News for panel recaps, exclusive Q&As, and much more.
- Join the conversation on X and LinkedIn, with hashtag #BIO2024. Watch for more exclusive video content and repost-worthy quotes.
- Watch your inbox for more right here each weekday at 10 AM ET/7 AM PT.
|
|
|
|
|
New reports define and quantify impacts of long COVID |
|
|
About 7% of all U.S. adults have had long COVID, according to new government-commissioned studies seeking to identify the scope of the condition and give it a unified definition.
What is long COVID? “An infection-associated chronic condition that occurs after SARS-CoV-2 infection and is present for at least 3 months as a continuous, relapsing and remitting, or progressive disease state that affects one or more organ systems,” says a report released Tuesday by the National Academies of Sciences, Engineering, and Medicine (NASEM).
Who gets it? Women are more likely to have long COVID—8.6% vs 5.1% of men, per a study released Friday. Race, ethnicity, income, and geographic location also impact the likelihood of having the condition.
Vaccines provide protection: Those with up-to-date COVID vaccines are least likely to get long COVID, studies show.
A few more interesting findings, from NASEM’s June 5 report: - “People whose infection was sufficiently severe to necessitate hospitalization are 2–3 times more likely to experience Long COVID.”
- There are more than 200 symptoms of long COVID.
- Long COVID manifests differently for each person and recovery time varies.
- Long COVID shares features with other “infection-associated chronic conditions affecting multiple body systems,” like myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), fibromyalgia, and postural orthostatic tachycardia syndrome.
What’s next: There is no single curative treatment, and current treatment only addresses symptoms, NASEM says. The search for an overall treatment continues.
Read more at Bio.News. |
|
|
|
|
|
|
President Biden’s Thursday: Signing a 10-year bilateral security agreement with Ukraine that commits the U.S. to military assistance during attendance of the G7 summit in Italy, per The Washington Post.
What’s Happening on Capitol Hill: The House Committee on Science, Space, and Technology will mark up several bills, including H.R. 8613, which “authorizes the National Science Foundation and the United States Department of Agriculture to conduct cross-cutting and collaborative research and development to enhance agricultural sustainability through advanced technological solutions.” |
|
|
|
|
